The placebo effect is a well-known psychological phenomenon that can lead to significant improvements in both clinical and non-clinical populations for self-report outcomes (e.g., self-rated ...

Ongoing open-label extension trials of simufilam in Alzheimer’s disease to be extended by up to an additional 36 months. The extension provides participants the opportunity to continue on treatment, ...

Phase 1b data shows treatment with SAT-3247 was safe and well-tolerated Pharmacokinetic (PK) profile of SAT-3247 translated as expected to Duchenne Muscular Dystrophy (DMD) patients taking concurrent ...

Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial Patients with stage III to IV or recurrent, radiographically ...

Amyotrophic lateral sclerosis (ALS) is a progressive, fatal neurodegenerative disorder for which there is no effective cure. Moreover, malnutrition significantly impacts the prognosis and overall ...

Preliminary results from the dose-escalation stage of a phase I trial of an anti-CCR8 antibody in patients with relapsed/refractory cutaneous T-cell lymphoma (R/R CTCL). A novel application of deep ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced data from a Phase 4 clinical trial evaluating the symptom stability, safety and tolerability of Cobenfy (xanomeline ...

MBX Biosciences Inc. (NASDAQ:MBX) shares dropped 19.6% in premarket trading on Friday despite the company reporting encouraging one-year clinical data for its investigational treatment canvuparatide ...

The benefit of beta-blockers after myocardial infarction in patients with a preserved left ventricular ejection fraction (LVEF) is unclear. We conducted a meta-analysis at the individual-patient level ...

Despite guideline recommendations, evidence for the use of non–vitamin K antagonist oral anticoagulant (NOAC) monotherapy in patients with atrial fibrillation after implantation of a drug-eluting ...

In a review published in NEJM Evidence, Massimo Di Maio, MD, from the Department of Oncology at the University of Turin in Turin, Italy, and president-elect of the Italian Association of Medical ...